Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Dimai, HP; Pietschmann, P; Resch, H; Preisinger, E; Fahrleitner-Pammer, A; Dobnig, H; Klaushofer, K; Austrian Society for Bone and Mineral Research (AuSBMR).
Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009
Wien Med Wochenschr Suppl. 2009; (122): 1-34. Doi: 10.1007/s10354-009-0656-x
PubMed FullText FullText_MUG Google Scholar


Führende Autor*innen der Med Uni Graz
Dimai Hans Peter
Co-Autor*innen der Med Uni Graz
Dobnig Harald
Fahrleitner-Pammer Astrid

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Osteoporosis is a systemic skeletal disease characterized by diminished bone mass and deterioration of bone microarchitecture, leading to increased fragility and subsequent increased fracture risk. Therapeutic measures therefore aim at reducing individual fracture risk. In Austria, the following drugs, all of which have been proven to reduce fracture risk, are currently registered for the treatment of postmenopausal osteoporosis: alendronate, risedronate, etidronate, ibandronate, raloxifene, teriparatide (1-34 PTH), 1-84 PTH, strontium ranelate and salmon calcitonin. Fluorides are still available, but their role in daily practice has become negligible. Currently, there is no evidence that a combination of two or more of these drugs could improve anti-fracture potency. However, treatment with PTH should be followed by the treatment with an anticatabolic drug such as bisphosphonates. Calcium and vitamin D constitute an important adjunct to any osteoporosis treatment.
Find related publications in this database (using NLM MeSH Indexing)
Austria -
Bone Density - drug effects
Bone Density Conservation Agents - adverse effects Bone Density Conservation Agents - therapeutic use
Evidence-Based Medicine -
Female -
Fractures, Spontaneous - prevention and control
Hip Fractures - prevention and control
Humans -
Osteoporosis, Postmenopausal - drug therapy
Randomized Controlled Trials as Topic -
Spinal Fractures - prevention and control

© Med Uni Graz Impressum